|Tested applications||WB IHC IF|
|Recommended Dilution||WB 1:500 - 1:2000
IHC 1:50 - 1:200
IF 1:20 - 1:50|
|Observed MW||Refer to Figures|
|Immunogen||A synthetic peptide of human BRCA1|
|Storage Buffer||Store at -20℃. Avoid freeze / thaw cycles.
Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.|
Immunohistochemistry of paraffin-embedded human prostate using BRCA1 antibody at dilution of 1:100 (40x lens).
Immunohistochemistry of paraffin-embedded mouse brain using BRCA1 antibody at dilution of 1:100 (40x lens).
Immunofluorescence analysis of A549 cells using BRCA1 antibody.
The breast cancer susceptibility proteins BRCA1 and BRCA2 are frequently mutated in cases of hereditary breast and ovarian cancers and have roles in multiple processes related to DNA damage, repair, cell cycle progression, transcription, ubiquitination and apoptosis (1-4). BRCA2 has been shown to be required for localization of Rad51 to sites of double stranded breaks (DSBs) in DNA, and cells lacking BRCA1 and BRCA2 cannot repair DSBs through the Rad51-dependent process of homologous recombination (HR) (5). Numerous DNA-damage induced phosphorylation sites on BRCA1 have been identified, including serines 988, 1189, 1387, 1423, 1457, 1524 and 1542, and kinases activated in a cell cycle-dependent manner, including Aurora A and CDK2, can also phosphorylate BRCA1 at Ser308 and Ser1497, respectively (6-10). Cell cycle-dependent phosphorylation of BRCA2 at Ser3291 by CDKs has been proposed as a mechanism to switch off HR as cells progress beyond S-phase by blocking the carboxy-terminal Rad51 binding site (11).
Neo Scientific welcomes feedback from its customers.
If you have used an our product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information.
If you have any additional inquiries please email technical services at firstname.lastname@example.org
Thank you for your support.